Literature DB >> 7544808

Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

J Schmitz1, J P Zimmer, B Kluxen, S Aries, M Bögel, I Gigli, H Schmitz.   

Abstract

Various immune mechanisms have been reported to contribute to the progressive destruction of Th cells in HIV-1-infected patients. Among these, complement mediated lysis of infected cells has been suggested. An increased sensitivity of lymphocytes from HIV-1-infected patients to lysis by monoclonal antibodies directed to MHC class I antigen and complement has been directly correlated with a decreased expression of the decay accelerating factor (CD55). It also has been reported that the expression of the membrane inhibitor of reactive lysis (CD59) is decreased during HIV-1 infection. We examined the effect of antibodies in the serum of HIV-1-positive individuals and normal human serum (NHS) as source of complement on several HIV-1-infected cell lines differing in their expression of CD55 and CD59. When HIV-1-infected target cells without membrane expression of CD55 and CD59 were used, a highly significant cytotoxic effect was observed in the presence of heat inactivated anti-HIV-1-positive sera and NHS, while heat-inactivated anti-HIV-1-negative sera and NHS were unable to induce cytolysis. Similar results were obtained using purified IgG isolated from HIV-1-positive sera and either NHS or guinea pig serum as source of complement. Lysis of HIV-1-infected cells correlated with expression of viral antigens on the cell surface. HIV-1-infected CD55 and CD59 positive target cells showed specific lysis, when the function of these molecules was abrogated by blocking antibodies to CD55 and CD59. The finding of anti-HIV-1-specific cytotoxic antibodies in sera from HIV-1-infected patients should be considered in the pathogenesis of the HIV-1-infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544808      PMCID: PMC185777          DOI: 10.1172/JCI118190

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Interaction of non-antibody factors with HIV in plasma.

Authors:  G T Spear
Journal:  AIDS       Date:  1993-09       Impact factor: 4.177

2.  Lysis of pathogenic and nonpathogenic Entamoeba histolytica by human complement: methodological analysis.

Authors:  C Hamelmann; B Foerster; G D Burchard; R D Horstmann
Journal:  Parasite Immunol       Date:  1992-01       Impact factor: 2.280

3.  Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.

Authors:  M R Posner; H S Elboim; T Cannon; L Cavacini; T Hideshima
Journal:  AIDS Res Hum Retroviruses       Date:  1992-05       Impact factor: 2.205

Review 4.  HIV and human complement: mechanisms of interaction and biological implication.

Authors:  M P Dierich; C F Ebenbichler; P Marschang; G Füst; N M Thielens; G J Arlaud
Journal:  Immunol Today       Date:  1993-09

5.  Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis.

Authors:  A Kojima; K Iwata; T Seya; M Matsumoto; H Ariga; J P Atkinson; S Nagasawa
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

6.  Tumour necrosis factor-alpha increases the sensitivity of human immunodeficiency virus (HIV)-infected monocytic U937 cells to the complement-dependent cytotoxicity of sera from HIV type 1-infected individuals; role of the gp120 protein.

Authors:  B Szabò; C Locardi; E Lo Presti; F Belardelli; A Benedetto
Journal:  J Gen Virol       Date:  1993-07       Impact factor: 3.891

7.  Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins.

Authors:  I A Rooney; A Davies; B P Morgan
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

8.  Complement activation by gp160 glycoprotein of HIV-1.

Authors:  N Thieblemont; N Haeffner-Cavaillon; L Weiss; F Maillet; M D Kazatchkine
Journal:  AIDS Res Hum Retroviruses       Date:  1993-03       Impact factor: 2.205

9.  Complement activation by recombinant HIV-1 glycoprotein gp120.

Authors:  C Süsal; M Kirschfink; M Kröpelin; V Daniel; G Opelz
Journal:  J Immunol       Date:  1994-06-15       Impact factor: 5.422

10.  Complement activation by human monoclonal antibodies to human immunodeficiency virus.

Authors:  G T Spear; D M Takefman; B L Sullivan; A L Landay; S Zolla-Pazner
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more
  25 in total

1.  CD59 incorporation protects hepatitis C virus against complement-mediated destruction.

Authors:  Tohti Amet; Marwan Ghabril; Naga Chalasani; Daniel Byrd; Ningjie Hu; Ayslinn Grantham; Ziqing Liu; Xuebin Qin; Johnny J He; Qigui Yu
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

2.  The Trojan exosome hypothesis.

Authors:  Stephen J Gould; Amy M Booth; James E K Hildreth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-28       Impact factor: 11.205

Review 3.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 4.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

5.  Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.

Authors:  R Herrero; L M Real; A Rivero-Juárez; J A Pineda; Á Camacho; J Macías; M Laplana; P Konieczny; F J Márquez; J C Souto; J M Soria; I Saulle; S Lo Caputo; M Biasin; A Rivero; J Fibla; A Caruz
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

Review 6.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

7.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

8.  Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization.

Authors:  Mohammad-Ali Jenabian; Héla Saïdi; Charlotte Charpentier; Hicham Bouhlal; Dominique Schols; Jan Balzarini; Thomas W Bell; Guido Vanham; Laurent Bélec
Journal:  AIDS Res Ther       Date:  2010-06-14       Impact factor: 2.250

9.  Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function.

Authors:  Hangeun Kim; Keith Meyer; Adrian M Di Bisceglie; Ranjit Ray
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.